Loading organizations...
Eisai is a global pharmaceutical company focused on the research, development, manufacture, and marketing of prescription drugs. It creates novel treatments across various therapeutic areas, leveraging scientific expertise to bring new medicines to patients worldwide. This integrated approach spans the entire lifecycle of pharmaceutical products, from discovery through commercialization.
The company was established in 1941 by Toyoji Naito. Naito, having worked with imported drugs, recognized the critical need for a robust domestic pharmaceutical industry in Japan during a transformative period. His vision stemmed from an ambition to contribute to public health by developing and supplying essential medicines, fostering national medical self-sufficiency.
Eisai serves patients globally through healthcare professionals, providing solutions for complex medical conditions. Its mission is to improve human health and well-being by continuously innovating and delivering high-quality pharmaceutical products. The company strives to address unmet medical needs and contribute meaningfully to better health outcomes for individuals, shaping the future of therapeutic care.
Key people at Eisai.
Key people at Eisai.
Eisai has 6 tracked investments across 6 companies. The latest tracked deal is $46.0M Series C in Casma Therapeutics in November 2022.